The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

The risks of 'miracle' weight loss jabs such as Ozempic, Wegovy and Mounjaro have been laid bare by a landmark study ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Underrepresentation of women as participants and researchers in CV clinical trials remains a problem, asserts a review ...

Oprah Winfrey is sparking a debate around weight, willpower and perception after the media mogul revealed her perceptions ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

In the trial, patients who received a once-weekly 20 mg injection of amycretin over 36 weeks saw an impressive 22% reduction ...

Eva Ehlich and Anja Fux of Maiwald discuss a board of appeal decision on G 2/21’s interpretation, including a critical review ...

For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers, including with respect to US Food and Drug Administration approval.